Hypovolemic Shock

4
Pipeline Programs
1
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

P
PharmazzIndia - Greater Noida
4 programs
1
2
1
CenthaquinePhase 41 trial
Normal SalinePhase 31 trial
Normal saline + Standard TreatmentPhase 31 trial
Normal SalinePhase 21 trial
Active Trials
NCT04056065Completed50Est. Oct 2018
NCT05251181Not Yet Recruiting430Est. Oct 2027
NCT04045327Completed105Est. Sep 2019
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
PharmazzCenthaquine
PharmazzNormal Saline
PharmazzNormal saline + Standard Treatment
PharmazzNormal Saline

Clinical Trials (4)

Total enrollment: 985 patients across 4 trials

NCT05956418PharmazzCenthaquine

A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients

Start: Aug 2021Est. completion: Aug 2026400 patients
Phase 4Recruiting
NCT05251181PharmazzNormal Saline

A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent

Start: Feb 2026Est. completion: Oct 2027430 patients
Phase 3Not Yet Recruiting
NCT04045327PharmazzNormal saline + Standard Treatment

Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock

Start: Jan 2019Est. completion: Sep 2019105 patients
Phase 3Completed
NCT04056065PharmazzNormal Saline

PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock

Start: May 2017Est. completion: Oct 201850 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 985 patients
1 companies competing in this space